Resolutions of the Annual Shareholders' Meeting of Sartorius Stedim Biotech S.A.
- Wall Street ends lower as investors await earnings, inflation data
- Microsoft (MSFT) announces $19.7 billion acquisition of Nuance (NUAN)
- Dollar drops as traders prepare for inflation data
Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.
AUBAGNE, France, March 24, 2021 /PRNewswire/ -- At today's virtual combined Annual General Shareholders' Meeting of Sartorius Stedim Biotech S.A., shareholders passed the resolution to pay a dividend of 0.68 euros per share for fiscal 2020. The total profit distributed will be 62.7 million euros. The previous year's dividend was 0.34 euros per share.
The Annual General Shareholders' Meeting granted discharge to all directors by a large majority.
This press release contains statements about the future development of the Sartorius Stedim Biotech Group. We cannot guarantee that the content of these statements will actually apply because these statements are based upon assumptions and estimates that harbor certain risks and uncertainties.
Financial calendar April 21, 2021: Publication of first-quarter figures (January to March 2021) July 21, 2021: Publication of first-half figures (January to June 2021) October 20, 2021: Publication of nine-month figures (January to September 2021)
A profile of Sartorius Stedim Biotech
Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry. As a total solutions provider, the company helps its customers to manufacture biotech medications safely, rapidly and economically. Headquartered in Aubagne, France, Sartorius Stedim Biotech is quoted on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and an international network of sales companies, Sartorius Stedim Biotech has a global reach. The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions of complementary technologies. In 2020, the company employed more than 7,500 people, and earned sales revenue of 1,910 million euros.
View original content to download multimedia:http://www.prnewswire.com/news-releases/resolutions-of-the-annual-shareholders-meeting-of-sartorius-stedim-biotech-sa-301255041.html
SOURCE Sartorius Stedim Biotech S.A.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Picosun increases efficiency for LED and OLED production
- NetAlly Launches LANBERT™ Media Qualification App for Testing Network Cabling for Multi-Gig/10Gbps
- CAIR-Minnesota Condemns City-Imposed Curfew on First Night of Ramadan, Seeks Exemption for Religious Purposes